[PDF]Scheme 1B - 2016-07-08 - Rackcdn.comhttps://75c17d9f6eecafb09b78-695e1a25d6559f5c6a6714b54be309d0.ssl.cf3.rackcd...
0 downloads
104 Views
208KB Size
UK NEQAS FOR H&I SCHEME 1B - HLA-B27 TESTING HLA-B27 TYPING RESULTS OF SAMPLES 1B07&08/2016 DESPATCHED ON 19TH JULY 2016 Summary of Results Total tested Positive Negative NT/Equivocal % Positive % Negative
123 0 123 2 0.0% 100.0%
122 0 122 3 0.0% 100.0%
Negative
Negative
Lab No 1 3 4 7 8 9 10 11 12 14 15 16 17 19 20 21 22 23 24 26 27
Result 1B07/2016 Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative
Result 1B08/2016 Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative
Date received 20-Jul 21-Jul 20-Jul 22-Jul 20-Jul 20-Jul 20-Jul 20-Jul 20-Jul 20-Jul 20-Jul 22-Jul 25-Jul 21-Jul 20-Jul 20-Jul 21-Jul 19-Jul 20-Jul 20-Jul 20-Jul
Date tested 29-Jul 21-Jul 08-Apr 22-Jul 20-Jul 22-Jul 20-Jul 25-Jul 28-Jul 22-Jul 22-Jul 26-Jul 07-Aug 27-Jul 25-Jul 20-Jul 22-Jul 28-Jul 26-Jul 20-Jul 20-Jul
28 29 31 32 34 35 37 39 40 41 42 45 46 47 48 54 55 57 58 62 66 67 68 72 76 78 83 84 85 86 90 93 96 101 103 104 106 107 108 109 110 111 112 113 115 126 127 128 129 130 131 133 137 142 153 154 156 158 174 176 185 198 199 209 219 223 225 232 234 236 245 253 255 256 257 269 273 276 278 279 285 288 292 295 300 305 306 307 310 317 319 323 324 325 326 327 329 334 339 340 348 349 353 356
Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative NT Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative NT Negative
Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative NT Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Equivocal Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative NT Negative
16-Jul 20-Jul 19-Jul 25-Jul 21-Jul 20-Jul 20-Jul 20-Jul 21-Jul 20-Jul 21-Jul 21-Jul 20-Jul 20-Jul 21-Jul 20-Jul 20-Jul 20-Jul 20-Jul 21-Jul 20-Jul 20-Jul 20-Jul 22-Jul 21-Jul 21-Jul 20-Jul 20-Jul 20-Jul 20-Jul 26-Jul 20-Jul 20-Jul 20-Jul 21-Jul 20-Jul 20-Jul 25-Jul 21-Jul 21-Jul 21-Jul 20-Jul 22-Jul 20-Jul 20-Jul 25-Jul 22-Jul 20-Jul 25-Jul 21-Jul 21-Jul 21-Jul 20-Jul 20-Jul 19-Jul 20-Jul 20-Jul 25-Jul 23-Jul 23-Jul 20-Jul 20-Jul 21-Jul 20-Jul 25-Jul 21-Jul 25-Jul 26-Jul 26-Jul 26-Jul 21-Jul 25-Jul 21-Jul 20-Jul 20-Jul 29-Jul 20-Jul 19-Jul 25-Jul 20-Jul 20-Jul 20-Jul 22-Jul 20-Jul 22-Jul 22-Jul 20-Jul 22-Jul 21-Jul 26-Jul 20-Jul 22-Jul 20-Jul 20-Jul 22-Jul 25-Jul 21-Jul 21-Jul 20-Jul 20-Jul 23-Jul 19-Jul
26-Jul 20-Jul 20-Jul 26-Jul
22-Jul 21-Jul 28-Jul 05-Aug 25-Jul 21-Jul 20-Jul 25-Jul 21-Jul 29-Jul 20-Jul 21-Jul 21-Jul 27-Jul 20-Jul 22-Jul NT 25-Jul 29-Jul 21-Jul 22-Jul 27-Jul 21-Jul 29-Jul 25-Jul 27-Jul 22-Jul 21-Jul 21-Jul 09-Aug 29-Jul 22-Jul 27-Jul 22-Jul 22-Jul 05-Aug 22-Jul 27-Jul 01-Aug 28-Jul 02-Aug 02-Aug 22-Jul 21-Jul 21-Jul 20-Jul 21-Jul 21-Jul 20-Jul 01-Aug 02-Aug 27-Jul 25-Jul 22-Jul 21-Jul 27-Jul 04-Aug 29-Jul 01-Aug 26-Jul 02-Aug 26-Jul 27-Jul 26-Jul 28-Jul 03-Aug 21-Jul 09-Aug 01-Aug 22-Jul 26-Jul 03-Aug 23-Jul 21-Jul 21-Jul 22-Jul 20-Jul 25-Jul 08-Aug 27-Jul 28-Jul 21-Jul 09-Aug 21-Jul 22-Jul 21-Jul 22-Jul 25-Jul 28-Jul 01-Aug 22-Jul 21-Jul 25-Jul 23-Jul 20-Jul
27-Jul
27-Jul
Consensus
Donor HLA type Donor HLA type
26-Jul
1B07/2016 1B08/2016
HLA-A3, A29; B7, B45; Cw6, Cw7; DR4, DR13; DQ6, DQ7 HLA-A1, A24; B8, B14; Cw2, Cw7; DR7, DR17; DQ2, DQ-
Source of pos/neg control cells used (if applicable)
Method SSP Flow Cytometry SSP Flow Cytometry Flow Cytometry SSP Luminex SSP SSP PCR-SSP SSP Flow Cytometry, SSP SSP, Luminex Flow Cytometry Flow Cytometry RT-PCR SSP SSP SSP Flow Cytometry SSO SSP/SSO Flow Cytometry Flow Cytometry SSP SSP SSP SSP Flow Cytometry SSP Luminex SSP Flow Cytometry Flow Cytometry SSP SSP SSP Flow Cytometry SSP SSP, SBT RT-PCR - TAQMAN Flow Cytometry Flow Cytometry SSP Flow Cytometry SSP Flow Cytometry Flow Cytometry, SSP RT-PCR SSP Flow Cytometry Flow Cytometry SSP SSP Flow Cytometry Flow Cytometry Flow Cytometry SSP SSP SSP Flow Cytometry, SSP Flow Cytometry SSP SSP SSP SSP Microarray Flow Cytometry, Luminex SSO Cytotoxicity, SSP Flow Cytometry Flow Cytometry, SSP Flow Cytometry RT-PCR Flow Cytometry SSP RT-PCR SSP SSP/SSO, Microarray Cytotoxicity SSP Flow Cytometry RT-PCR SSP SSP SSP SSP SSP Molecular SSO RT-PCR RT-PCR Flow Cytometry SSP SSP SSP/RT-PCR Microarray Cytotoxicity Cytotoxicity Flow Cytometry Cytotoxicity Flow Cytometry SSP SSP SSP SSP Flow Cytometry SSP RT-PCR Cytotoxicity Flow Cytometry SSP Flow Cytometry SSP SSO Flow Cytometry SSP PCR-SSP Flow Cytometry Flow Cytometry
In-house Enzo Life Sciences Control included in assay In-house
In-house
Primers and Probes Alta Bioscience
PCR-SSP Detection system Gel
Own design
Fluorescence
Own design
Gel
Own design Own design
Gel Gel
Olerup Olerup Own design
Gel Gel Gel
In-house Own design Olerup Own design
Gel Gel Gel
High Resolution Typing HLA-B*27 alleles 1B07/2016 1B08/2016
Comments
In-house In-house (previous NEQAS scheme samples)
Neg = Immunotrol cells (Beckman Coulter) Pos = Pheonix Flow CRISP HLA B27 pos cells In-house Positive control cells not used
In-house Axxora In-house
Biofortuna Phoenix Flow
Gel
Olerup Own design Own design Own design
Gel Gel Gel, Fluorescence Gel
Own design
Gel
Own design
Gel
Invitrogen Own design Hain Lifesciences
Gel Gel Fluorescence
Innotrain Olerup Own design
Gel Fluorescence
TIB MOLBIOL
Fluorescence
Commercial
Gel
Olerup Own design Invitrogen
Gel Fluorescence (Taqman probes) Gel
Olerup Olerup
Gel Gel
EuroImmun
Fluorescence Gel
In-house Secore
Crisp HLA-B27
HLA B27 CRISP positive control cells Enzo Life Sciences In-house In-house Beckman+One Lambda Olerup
Method under validation
Phoenix
LinkSeq HLA-B27 Commercial
Gel
Own design Olerup Olerup Own design
Gel Gel Gel Fluorescence
Olerup
Gel
Olerup
Gel
Olerup
Gel
Olerup
Gel Gel
Olerup
Gel
Linkafe Biosciences Commercial Clonit Invitrogen Commercial Olerup
Fluorescence Gel Fluorescence Gel Gel Gel
Olerup EuroImmun Olerup Linkage biosciences
Gel
Innotrain Commercial Sciences Biomark inc Olerup
Gel Gel Fluorescence Gel
Olerup
Gel
BAG Healthcare
Gel
AnDiaTec
Gel Fluorescence
Own design Own design
Fluorescence Fluorescence
In-house
In-house
Phoenix BD
In-house, Commercial
Invitrogen In-house In-house UK NEQAS 1B
Commercial
Gel Melting Point
In-house
In-house In-house
In-house Bionobis
In-House
Method under validation
Flow Cytometry
UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
NEQ-115 Issue 1 P. 1 of 2 Effective Date 10/03/16
UK NEQAS FOR H&I SCHEME 1B - HLA-B27 TESTING HLA-B27 TYPING RESULTS OF SAMPLES 1B07&08/2016 DESPATCHED ON 19TH JULY 2016 Lab No 3 7 17 20 21 27 31 32 40 46 47 57 67 68 76 83 84 90 93 103 104 106 110 111 128 131 133 137 153 198 256 288 295 310 324 326 334 348 349 356
Monoclonal 1 Designation HLA-B27 FITC FITC B27 FITC Anti B27-FITC/CD3-PE HLA-B27 Duraclone B27 MSIgG1 RDI/MsIgG2a FITC PF/FITC HLA-B27 PE Anti HLA-B27 ABC m3 IgG2a IgG2a PE- anti-Human-HLA-B27 HLA-B27/B7 FD705 HLA-B27 B7/B27 HLA-B27 B27 HLA-B27-FITC/HLA-B7-PE Anti-HLA-B27 HLA-B27 Anti-HLA-B27 FITC Anti-HLA-B27 FITC Iotest HLA-B27 FITC HLA-B27-FITC/HLA-B7-PE
Monoclonal 1 Specificity Clone GS145.2 Anti-HLA-B27 B27 B27+B7 HLA-B27 FITC CD3, HLA-B27, HLA-B7 Isotype control B7/B27
HLA-ABC m3/BB7.1 HLA-B27 FITC HLA-B27 testing on T-cells Anti-HLA-B27 Anti-HLA-B27 FITC Anti-HLA-B27 FITC Iotest HLA-B27 FITC/B7 PE HLA-B27 FITC Iotest HLA-B27 FITC, HLA-B7 PE HLA-B27 FITC CD3 PE/HLA-B27 FITC Anti-CD3 PE Duraclone B27
HLA-B27/B7 IgG2b FD705 anti-HLA-B27 FITC + anti-CD3-PE HLA-B27 HLA-B27 Clone GS145.2 HLA-B27 HLA-B27 HLA-B27
FITC HLA-B27 HLA-B27 clone FD705 and ABCm3 HLA-B27-FITC/B7-PE HLA-B27 FITC B7/B27 R-PE B27 HLA-B27 FITC/CD3 PE HLA-B27 FD705-9E1E10 Clone GS145.2 HLA-B27 HLA-B27
HLA-B27 CD3, Clone UCHT1
Monoclonal 1 Manufacturer BD BD One Lambda BD One Lambda Beckman Coulter Beckman Coulter Beckman Coulter Beckman Coulter BD Beckman Coulter Beckman Coulter Beckman Coulter Beckman Coulter Beckman Coulter Beckman Coulter Beckman Coulter Beckman Coulter One Lambda Beckman Coulter BD One Lambda One Lambda BD Beckman Coulter Beckman Coulter BD Immunotech One Lambda BD BD BD and Beckman Coulter BD Beckman Coulter Beckman Coulter Beckman Coulter Beckman Coulter BD BD Beckman Coulter
Monoclonal 2 Designation CD3 PE PE/FITC CD3 PE Anti B27-FITC HLA-B27/HLA-B7
Monoclonal 2 Specificity Clone SK7 Anti CD3 CD3 B27 HLA-B27-FITC/HLA-B7-PE
Monoclonal 2 Monoclonal 3 Manufacturer Designation BD BD BD One Lambda Beckman Coulter
HLA-B27 FITC/B7 PE PE/FITC CD3-PE-DY649 Anti CD3 FD705 IgG2b IgG2b PE- Dyomics649- anti-Human CD3 HLA-B27 ABCm3 HLA-B7
B7/B27 IgG/IgG2 PE HLA-B27 HLA-B27 clone UCHT1 HLA-B27-FITC HLA-B27 PE
Beckman Coulter Beckman Coulter Beckman Coulter BD Beckman Coulter Beckman Coulter Beckman Coulter One Lambda Beckman Coulter Beckman Coulter
CD3 B27
PE-Dyomics649 B27
Beckman Coulter B7 Beckman Coulter
HLA-B27
HLA-B7/B27
Immunotech
CD3 PE Iotest HLA-B7 PE
Clone SK7 HLA-B7
BD Beckman Coulter CD45 PerCp-Cy5.5
MPC-11 HLA-B27-FITC/B7-PE HLA-B27 control +B7 crossreaction Anti-CD3 Anti-CD3 PE Anti-CD3 PE Iotest HLA-B27 FITC/B7 PE HLA-B7 PE MO AB B27 FITC HLA-B7 PE
HLA-B27 IgG2a-IgG1 anti-HLA-B27 FITC + anti-CD3-PE CD3 CD3 Clone SK7 HLA-B7 HLA-B7 HLA-B27
BD One Lambda Immunotech Beckman Coulter Isotype control BD BD Anti-HLA-B7 PE BD Beckman Coulter Beckman Coulter One Lambda Beckman Coulter
Anti HLA-B27 FITC Duraclone B27
HLA-B27, Clone ABCm3
Monoclonal 3 Specificity
Monoclonal 3 Manufacturer
BB7.1 IgG1 IgG1K unlabeled anti-Human B7
HLA-B7 CD3 Clone BB7.1
Beckman Coulter Beckman Coulter Beckman Coulter
BB7.1 CD3
HLA-B7 PC5
Beckman Coulter Beckman Coulter
Clone BB7.1
Beckman Coulter
Lymphocytes gating
BD
BD Beckman Coulter Duraclone B27
IgG2a-FITC and IgG1-PE Beckman Coulter HLA-B7
Beckman Coulter
HLA-B27, Clone FD705
Beckman Coulter
NEQ-115 Issue 1 UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351. © Confidential report; no data may be published without permission from UK NEQAS for H+I
P. 2 of 2 Effective Date 10/03/16
